Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in CLL Six-year median follow-up from the ...
Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...
The FDA approved Venclexta and Gazyva for frontline CLL/SLL treatment, based on the phase 3 CLL14 trial results. The combination reduced disease progression or death risk by 67% compared to Gazyva ...
New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic leukemia (CLL). A pair of studies examining the role of venetoclax ...
Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
Combination therapies for chronic lymphocytic leukemia (CLL) offer improved depth of response and potentially longer survival times compared with single-agent treatments. They target different ...
Hosted on MSN
AbbVie’s venetoclax study completion: Implications for CLL treatment and market dynamics
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie has recently completed a clinical study titled ‘Venetoclax (Venclexta Tablet) Post-Marketing Surveillance for CLL Patients.’ ...
Fixed-duration Venclexta/Gazyva or Venclexta/Imbruvica therapies show noninferior progression-free survival compared to continuous Imbruvica in untreated CLL patients. Three-year progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results